JPWO2022232653A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022232653A5 JPWO2022232653A5 JP2023563934A JP2023563934A JPWO2022232653A5 JP WO2022232653 A5 JPWO2022232653 A5 JP WO2022232653A5 JP 2023563934 A JP2023563934 A JP 2023563934A JP 2023563934 A JP2023563934 A JP 2023563934A JP WO2022232653 A5 JPWO2022232653 A5 JP WO2022232653A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- subject
- paclitaxel
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182519P | 2021-04-30 | 2021-04-30 | |
| US63/182,519 | 2021-04-30 | ||
| US202163193381P | 2021-05-26 | 2021-05-26 | |
| US63/193,381 | 2021-05-26 | ||
| US202263313882P | 2022-02-25 | 2022-02-25 | |
| US63/313,882 | 2022-02-25 | ||
| PCT/US2022/027142 WO2022232653A1 (en) | 2021-04-30 | 2022-04-29 | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519449A JP2024519449A (ja) | 2024-05-14 |
| JPWO2022232653A5 true JPWO2022232653A5 (https=) | 2025-05-09 |
| JP2024519449A5 JP2024519449A5 (https=) | 2025-05-09 |
Family
ID=83847357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563934A Pending JP2024519449A (ja) | 2021-04-30 | 2022-04-29 | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240182583A1 (https=) |
| EP (1) | EP4329808A4 (https=) |
| JP (1) | JP2024519449A (https=) |
| AU (1) | AU2022264597A1 (https=) |
| CA (1) | CA3217833A1 (https=) |
| IL (1) | IL308020A (https=) |
| WO (1) | WO2022232653A1 (https=) |
| ZA (1) | ZA202309774B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020223704A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Anti-galectin-9 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312910B1 (en) * | 2017-10-27 | 2026-02-01 | Univ New York | Anti-galectin-9 antibodies and their uses |
| WO2020223704A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Anti-galectin-9 antibodies and uses thereof |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
-
2022
- 2022-04-29 WO PCT/US2022/027142 patent/WO2022232653A1/en not_active Ceased
- 2022-04-29 JP JP2023563934A patent/JP2024519449A/ja active Pending
- 2022-04-29 AU AU2022264597A patent/AU2022264597A1/en not_active Abandoned
- 2022-04-29 CA CA3217833A patent/CA3217833A1/en active Pending
- 2022-04-29 US US18/556,394 patent/US20240182583A1/en active Pending
- 2022-04-29 EP EP22796898.9A patent/EP4329808A4/en active Pending
- 2022-04-29 IL IL308020A patent/IL308020A/en unknown
-
2023
- 2023-10-19 ZA ZA2023/09774A patent/ZA202309774B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pinter et al. | Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo | |
| JP2020011980A5 (https=) | ||
| JP6255086B2 (ja) | 癌のための併用療法 | |
| JP2022526694A (ja) | 腫瘍治療用の併用医薬組成物 | |
| JP2021510697A5 (https=) | ||
| EP4406538A1 (en) | Treatment of cancer patients having kras mutations | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| TW202128224A (zh) | 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 | |
| JP2025156341A (ja) | ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| JP2021511344A5 (https=) | ||
| WO2005097086A2 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
| JPWO2021022256A5 (https=) | ||
| JPWO2022232653A5 (https=) | ||
| CN115485029A (zh) | 用于肝癌的miv-818/乐伐替尼组合疗法 | |
| WO2025061110A1 (zh) | 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途 | |
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| JPWO2020223702A5 (https=) | ||
| Brandi et al. | Durable complete response of hepatocellular carcinoma after metronomic capecitabine | |
| Ezaki et al. | A case of gemcitabine and cisplatin chemotherapy in a patient with metastatic urothelial carcinoma receiving hemodialysis | |
| JPWO2019144098A5 (https=) | ||
| JPWO2022232641A5 (https=) | ||
| EP3733202A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| HK40122430A (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| EP4702989A1 (en) | Drug for treating locally advanced unresectable or metastatic colorectal cancer and use thereof |